drugset
drugset / Trial / NCT04395716

A Study of ResCure™ to Treat COVID-19 Infection

NCT04395716 ↗

Phase 1 Withdrawn ProgenaBiome Rinati Skin, LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection.

Timeline

Start
2020-01
Primary completion
2021-06
Completion
2021-11

Outcome

Outcome not reported

Stopped: “Not ever started”

Drugs

EvaluationDrugModalityDoseRoute
Subject ResCure™ Unknown — Inhaled

Indications

COVID-19 severe acute respiratory syndrome